Recalls selected batches of disopyramide phosphate, SMXrI'MP tablets, cephalexin oral powder, amoxicillin chewable tablets and halts production of liquid amoxicillin for humans and animals, liquid ampicillin, amiloride and liquid nystatin as part of consent decree reached with the Justice Department July 28. Biocraft announced July 21 that it was halting shipments of nystatin oral suspension and amoxicillin powder for oral suspension and as part the pending consent decree ("The Pink Sheet" July 25, T&G-1)
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth